Actively Recruiting
Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2025-03-18
50
Participants Needed
1
Research Sites
415 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prevalence of myopia and its complications has been increasing over the past decades, especially among children and adolescents. It reaches record levels in Asia: nearly 80% of the population in some regions in 2012 where the investigators speak in terms of epidemic. ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose results are promising. The investigators use this eye drops in our clinical practice at hospital of Saint-Etienne since 2017. Few clinical data have been published so far concerning the French population. The investigators would like to build a database so that the investigators can publish our results and share our experience.
CONDITIONS
Official Title
Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children with active myopia treated with ATROPINE 0.01% eye drops
- Patient affiliated with a social security organization
- Agreement of both parents
You will not qualify if you...
- Non compliance with treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Saint Etienne
Saint-Etienne, France, 42055
Actively Recruiting
Research Team
M
Marie Caroline TRONE
CONTACT
M
Marie PEURIERE
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here